A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-421286 in Subjects With Advanced Solid Tumors
Latest Information Update: 07 Feb 2024
At a glance
- Drugs BPI-421286 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Betta Pharmaceuticals Co Ltd
Most Recent Events
- 14 Apr 2022 New trial record